THE TREATMENT OF MALIGNANT DISEASE BY REGIONAL CHEMOTHERAPY.
D000963:Antimetabolites; D000970:Antineoplastic Agents; D002294:Carcinoma, Squamous Cell; D010478:Chemotherapy, Cancer, Regional Perfusion; D003609:Dactinomycin; D005853:Geriatrics; D006258:Head and Neck Neoplasms; D006801:Humans; D007263:Infusions, Parenteral; D008545:Melanoma; D008558:Melphalan; D008727:Methotrexate; D009062:Mouth Neoplasms; D009369:Neoplasms; D009379:Neoplasms, Muscle Tissue; D009588:Nitrogen Mustard Compounds; D012509:Sarcoma; D014116:Toxicology; D014265:Triethylenemelamine
D000963:Antimetabolites; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D003609:Dactinomycin; D014265:Triethylenemelamine; D008558:Melphalan; D008727:Methotrexate
ACTINOMYCIN; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; CARCINOMA, EPIDERMOID; GERIATRICS; INFUSIONS, PARENTERAL; ISOLATION PERFUSION; MELANOMA; MELPHALAN; METHOTREXATE; MOUTH NEOPLASMS; NECK NEOPLASMS; NEOPLASMS, MUSCLE TISSUE; NITROGEN MUSTARD COMPOUNDS; SARCOMA; TOXICOLOGIC REPORT; TRIETHYLENE MELAMINE